Veritas In Silico - Signed a joint development and commercialization agreement with Liverpool ChiroChem in the UK.

Veritas In Silico ＜130A＞ announced on the 23rd that it has entered into a joint development and commercialization agreement with Liverpool ChiroChem (LCC) for RNA-targeted low molecular weight Pharmaceuticals. Starting from July 2024, the company will utilize LCC's chemical platform PACETM to access over 1,000 new chiral fragments through its drug discovery platform ibVIS, aimed at cancer diseases, rare diseases, and central nervous system disorders.

Fisco JapanDec 24 18:08

Veritas In Silico, Liverpool ChiroChem Partner on MRNA-targeted Drug Development

MT NewswiresDec 24 08:28

Fanpepp ETC [Stocks with intriguing features from the change in Volume]

Stock closing price compared to the previous day Volume * <7897> Hokkshin 1,121,311,006,300 * <4881> FanPep 1,724,532,232,100 * <3377> Bike King 503,606,318,00 * <3111> Omi Kenshi 298,256,178,00 * <7325> Iric 670,251,714,00 * <130A> VIS 713,184,502,00 * <6176> Brangista 772,923,769,00 * <4784> GMO-AP 829,441,394,300 *

Fisco JapanDec 24 06:44

Three key points to focus on in the afternoon session - favorable developments with buying strong due to the rise in U.S. stocks.

In the afternoon session of the 23rd, I'd like to focus on the following three points. ・The Nikkei average rebounds, with buying dominating due to the rise in US stocks. ・The dollar-yen pair is slowing down its decline, maintaining high US interest rates. ・The top contributor to price increases is Advantest <6857>, with Recruit Holdings <6098> in second place. ■ The Nikkei average rebounds, with buying dominating due to the rise in US stocks. The Nikkei average has rebounded, closing the morning session at 39,043.59 yen, up 341.69 yen (Volume estimated at 0.9 billion, 41.33 million shares). Last week's US market's Dow Inc.

Fisco JapanDec 23 11:42

Stocks reaching the upper and lower limits in the first half of the trading session.

■Limit up <130A> Veritas In Silico <6176> Branjista <7681> Leocran <8783> GFA ■Limit down *Includes temporary limit up/down (indicative price).

Fisco JapanDec 23 11:04

Veritas In Silico---Revision of the Financial Estimates for the full year ending December 2024.

On the 13th, Veritas In Silico <130A> announced a revision of its financial estimates for the fiscal year ending December 2024, based on recent performance trends. The revised financial estimates for the fiscal year 2024 (January-December 2024) show business revenue decreased by 72.0% compared to the previous estimate to 0.189 billion yen, an operating profit of a negative 0.214 billion yen, ordinary profit of a negative 0.235 billion yen, net income of a negative 0.238 billion yen, and net income per share to

Fisco JapanDec 17 17:09